Description
Brazil
Canada - English
Canada - Français
Deutschland
France
Ελλάδα
Ireland
Latin America
Netherlands
Spain
Switzerland
United Kingdom
United States
日本
29 May 2020 New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
14 May 2020 New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
12 December 2019 New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
30 September 2019 New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 August 2019 New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer
21 June 2019 German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June 2019 Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
3 June 2019 Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer
25 March 2019 New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy
19 December 2018 NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
10 December 2018 New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions
22 October 2018 New real-world evidence confirms utility of the Oncotype DX test in clinical practice for patients with early-stage breast cancer
7 September 2018 German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
23 March 2018 New real-world clinical practice data reinforce the value of the Oncotype DX Breast Recurrence Score test for patients, physicians and the health care system
11 December 2017 New validation shows Oncotype DX Breast Recurrence Score test predicts clinical response to neoadjuvant hormonal therapy to improve surgical outcomes in certain patients with large tumors
11 September 2017 New analysis from German study group prospective trial shows minimal distant recurrence in patients with clinically high-risk breast cancer and low Oncotype DX Breast Recurrence Score results following five years of hormone therapy alone
12 July 2017 Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer
6 June 2017 New data show important role of genomic testing in treatment of older breast cancer patients
17 March 2017 Genomic Health unveils a wealth of data for the Oncotype DX breast cancer test, reinforcing its value in improving patient outcomes and leading to more cost-effective management
This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.